Overview

Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115

Status:
Completed

Trial end date:
2017-11-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Adalimumab